Research Papers
Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
David Bakish, Anjana Bose, Carl Gommoll, Changzheng Chen, Rene Nunez, William M. Greenberg, Michael Liebowitz and Arif Khan
J Psychiatry Neurosci January 01, 2014 39 (1) 40-49; DOI: https://doi.org/10.1503/jpn.130040
David Bakish
Bakish — Ottawa Psychopharmacology Clinic, Ottawa, Ont., Canada; Bose — Forest Research Institute, at time of study, Jersey City, NJ, USA; Gommoll, Chen, Nunez, Greenberg — Forest Research Institute, Jersey City, NJ, USA; Liebowitz — Columbia University and The Medical Research Network, New York, NY, USA; Khan — Northwest Clinical Research Center, Bellevue, Wash., USA; and the Department of Psychiatry and Behavioral Sciences, Duke University Medical School, Durham, NC, USA
MDAnjana Bose
Bakish — Ottawa Psychopharmacology Clinic, Ottawa, Ont., Canada; Bose — Forest Research Institute, at time of study, Jersey City, NJ, USA; Gommoll, Chen, Nunez, Greenberg — Forest Research Institute, Jersey City, NJ, USA; Liebowitz — Columbia University and The Medical Research Network, New York, NY, USA; Khan — Northwest Clinical Research Center, Bellevue, Wash., USA; and the Department of Psychiatry and Behavioral Sciences, Duke University Medical School, Durham, NC, USA
PhDCarl Gommoll
Bakish — Ottawa Psychopharmacology Clinic, Ottawa, Ont., Canada; Bose — Forest Research Institute, at time of study, Jersey City, NJ, USA; Gommoll, Chen, Nunez, Greenberg — Forest Research Institute, Jersey City, NJ, USA; Liebowitz — Columbia University and The Medical Research Network, New York, NY, USA; Khan — Northwest Clinical Research Center, Bellevue, Wash., USA; and the Department of Psychiatry and Behavioral Sciences, Duke University Medical School, Durham, NC, USA
MSChangzheng Chen
Bakish — Ottawa Psychopharmacology Clinic, Ottawa, Ont., Canada; Bose — Forest Research Institute, at time of study, Jersey City, NJ, USA; Gommoll, Chen, Nunez, Greenberg — Forest Research Institute, Jersey City, NJ, USA; Liebowitz — Columbia University and The Medical Research Network, New York, NY, USA; Khan — Northwest Clinical Research Center, Bellevue, Wash., USA; and the Department of Psychiatry and Behavioral Sciences, Duke University Medical School, Durham, NC, USA
PhDRene Nunez
Bakish — Ottawa Psychopharmacology Clinic, Ottawa, Ont., Canada; Bose — Forest Research Institute, at time of study, Jersey City, NJ, USA; Gommoll, Chen, Nunez, Greenberg — Forest Research Institute, Jersey City, NJ, USA; Liebowitz — Columbia University and The Medical Research Network, New York, NY, USA; Khan — Northwest Clinical Research Center, Bellevue, Wash., USA; and the Department of Psychiatry and Behavioral Sciences, Duke University Medical School, Durham, NC, USA
MDWilliam M. Greenberg
Bakish — Ottawa Psychopharmacology Clinic, Ottawa, Ont., Canada; Bose — Forest Research Institute, at time of study, Jersey City, NJ, USA; Gommoll, Chen, Nunez, Greenberg — Forest Research Institute, Jersey City, NJ, USA; Liebowitz — Columbia University and The Medical Research Network, New York, NY, USA; Khan — Northwest Clinical Research Center, Bellevue, Wash., USA; and the Department of Psychiatry and Behavioral Sciences, Duke University Medical School, Durham, NC, USA
MDMichael Liebowitz
Bakish — Ottawa Psychopharmacology Clinic, Ottawa, Ont., Canada; Bose — Forest Research Institute, at time of study, Jersey City, NJ, USA; Gommoll, Chen, Nunez, Greenberg — Forest Research Institute, Jersey City, NJ, USA; Liebowitz — Columbia University and The Medical Research Network, New York, NY, USA; Khan — Northwest Clinical Research Center, Bellevue, Wash., USA; and the Department of Psychiatry and Behavioral Sciences, Duke University Medical School, Durham, NC, USA
MDArif Khan
Bakish — Ottawa Psychopharmacology Clinic, Ottawa, Ont., Canada; Bose — Forest Research Institute, at time of study, Jersey City, NJ, USA; Gommoll, Chen, Nunez, Greenberg — Forest Research Institute, Jersey City, NJ, USA; Liebowitz — Columbia University and The Medical Research Network, New York, NY, USA; Khan — Northwest Clinical Research Center, Bellevue, Wash., USA; and the Department of Psychiatry and Behavioral Sciences, Duke University Medical School, Durham, NC, USA
MD
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
David Bakish, Anjana Bose, Carl Gommoll, Changzheng Chen, Rene Nunez, William M. Greenberg, Michael Liebowitz, Arif Khan
J Psychiatry Neurosci Jan 2014, 39 (1) 40-49; DOI: 10.1503/jpn.130040
Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
David Bakish, Anjana Bose, Carl Gommoll, Changzheng Chen, Rene Nunez, William M. Greenberg, Michael Liebowitz, Arif Khan
J Psychiatry Neurosci Jan 2014, 39 (1) 40-49; DOI: 10.1503/jpn.130040
Related Articles
Cited By...
- No citing articles found.